Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2007-12-04
2011-12-13
Azpuru, Carlos A (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S468000
Reexamination Certificate
active
08075914
ABSTRACT:
A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient.
REFERENCES:
patent: 5508039 (1996-04-01), Yates et al.
patent: 5648727 (1997-07-01), Tyberg et al.
patent: 5688643 (1997-11-01), Oka et al.
patent: 5700828 (1997-12-01), Federowicz et al.
patent: 5750557 (1998-05-01), Zisapel
patent: 5849338 (1998-12-01), Richardson et al.
patent: 6096561 (2000-08-01), Tayi
patent: 0 518 468 (1992-12-01), None
patent: 9623496 (1996-08-01), None
Arangino, Serenella et al., “Effects of Melatonin on Vascular Reactivity, Catecholamine Levels, and Blood Pressure in Healthy Men,” American Journal of Cardiology, May 1, 1999, pp. 1417-1419, vol. 83(9).
Birau, Nikolaus et al., “Hypotensive Effect of Melatonin in Essential Hypertension,” IRCS Medical Science. 1981, p. 906, vol. 9, No. 10.
Brugger, P. et al., “Impaired nocturnal secretion of melatonin in coronary heart disease,” The Lancet, Jun. 3, 1995, p. 1408, vol. 345.
Lusardi, P. et al. “Effect of bedtime melatonin ingestion on blood pressure or normotensive subjects,” Blood Pressure Monitoring, 1997, pp. 99-103, vol. 2(2).
Zaslavskaia, RM et al., “Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension,” Klin Med (Mosk), 1998, pp. 49-51, vol. 76(12). Abstract PMID: 10067294.
Zaslavskaia, RM et al., “Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II,” Ter Arkh., 1999, pp. 21-24, vol. 71(12). Abstract PMID 10647194.
Zaslavskaia,, RM et al., Comparative Evaluation of the effectiveness of Monotherapy of Elderly Patients with Hypertension Using Kozaar and Combined Therapy with Kozaar and Melatonin, Clinical Medicine, 1999, No. 12, pp. 1-7.
Zaslavskaia, RM et al., “Effects of Therapy with Melatonin and Its Combinations with Aceten on the Time Structure of Circadian Hemodynamic Rhythms in Patients with Stage II Hypertension,” Ter Arkh., 1999, No. 12, pp. 21-24.
Anderson et al., “Melatonin Potentiates Testosterone-induced Suppression of Luteinizing Hormone Secretion in Normal Men”, Hum Reprod. 8(11), 1993, pp. 1819-1822.
Brown et al., “Psychometric Analyses of Chronotype Measurement Scales” Biological Rhythm Research, 1995, 26: p. 373.
Brzezinski, “Melatonin in Humans”, N. Engl. J. Med, 336, 1997, pp. 186-195.
Cagnacci et al., “Influences of Melatonin Administration on the Circulation of Women”, Am J Physiol Regul Integr Comp Physiol 274, 1998, pp. R335-R338.
Cagnacci et al., “Melatonin Enhances Cortisol Levels in Aged Women: Reversible by Estrogens”, J. Pineal Res., 22(2), 1997, pp. 81-85.
Capsoni et al, “Reduction of Regional Cerebral Blood Flow by Melatonin in Young Rats”, Neuroendocrinology, Neuro Report 6, 1995, pp. 1346-1348.
Fagan, “Diltiazem: Its Place in the Antihypertensive Armamentarium”, Journal of Cardiovascular Pharmacology, vol. 18 (Suppl. 9), 1991, pp. 526-531.
Gandhi et al., “Resistant Hypertension: Suggestions for dealing with the problem”, vol. 100, No. 4, 1996, pp. 1-11.
Kostis et al, “CNS side effects of centrally-active antihypertensive agents: a prospective, placaebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males”, Psychopharmacology, 102, 1990, pp. 163-170.
Kostoglou-Athanassiou, “Melatonin Administration and Pituitary Hormone Secretion”, Clin. Endocrinol (Oxf), 48(1) 1998, pp. 31-37.
Kulczykowska, “Effects of Arginine Vasotocin, Isotocin and Melatonin on Blood Pressure in the Conscious Atlantic Cod (Gadus morhua): Hormonal Interactions?”, Exp Physiol. 83(6), 1998, 1 page.
Litchtenfeld et al., Hypertension, Increased Urinary Free Cortisol: A potential Intermediate Phenotype of Essential Hypertension, 31, 1998, pp. 569-574.
Macfarlane et al., “The Effects of Exogenous Melatonin on the Total Sleep Time and Daytime Alertness of Chronic Insomniacs: A Preliminary Study”, Biol. Psychiatry, 30, 1991, pp. 371-376.
Mahle et al., “Melatonin Modulates Vascular Smooth Muscle Tone”, J. of Biol. Rhythms, 12: 690, 1997, pp. 690-696.
Matsumura et al., “Modulation of Circadian Rhythm of Blood Pressure by Cortisol in Patents with Hypopituitarism”, Clin. And Exper. Hypertension, 16(1), 1994, pp. 55-66.
Morley et al., “Endocrinology and Metabolism in the Elderly” Blackwell Scientific Publications, 1992, pp. 70-91.
Nichols et al., “Gene Products of Corticosteroid Action in Hippocampus”, Annals of the New York Academy of Science, 746, 1994, pp. 145-154.
Penev et al., “Melatonin: A Clinical Perspective”, Ann Neurol, 42, No. 4, 1997, 545-553.
Satake et al., “The Mode of Vasorelatxing Action of Melatonin in Rabbit Aorta”, Gen. Pharmacol., vol. 22, No. 2, 1991, pp. 219-221.
Scalbert et al., “Melatonine et regulation du system cardiovasculaire”, J. Therapie, 53, 1998, pp. 459-465.
Shaw, “Hypothalamo-pituitary-adrenal Function in Parkisonian Patients Treated with Melatonin”, curr Med Res Opin. 1976-1977; 4(10): 743-6.
Smythe et al., “Suppression of Human Growth Hormone Secretion by Melatonin and Cyproheptadine”, J. Clin Invest. 54(1), 1974, pp. 116-121.
Tan et al., “Ischemia/reperfusion-induced Arrhythmias in the Isolated rat heart: Prevention by Melatonin”, J. Pin. Res., 25, 1998, pp. 184-191.
Terzolo et al., “Effects of Long-Term, Low-Dose, Time-Specified Melatonin Administration of Endocrine and Cardiovascular Variables in Adult Men”, J. Pineal. Res, 9, 1990, pp. 113-124.
Valcavi et al., “Effect of Oral Administration of Melatonin on GH Responses to GRF 1-44 in Normal Subjects”, Clin Endocrinol (Oxf). 26(4), 1987, pp. 453-458.
Laudon Moshe
Zisapel Nava
Azpuru Carlos A
Neurim Pharmaceuticals (1991) Ltd.
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Method and formulation for treating resistance to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and formulation for treating resistance to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and formulation for treating resistance to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310300